ARCT Earnings & Financial Statements
Arcturus Therapeutics Holdings Inc.
$10.93
-$0.19(-1.71%)
43
Overall
60
Value
40
Tech
31
Quality
Market Cap
$316.06M
Volume
196.08K
52W Range
$5.50 - $24.17
Target Price
$22.00
ARCT earnings and financial statements: Arcturus Therapeutics Holdings Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ARCT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $82.03M | $152.31M | $166.80M | $205.75M | $12.36M |
| Operating income | -$76.26M | -$95.67M | -$78.20M | $12.18M | -$202.85M |
| EBITDA | -$62.76M | -$77.40M | -$24.93M | $15.17M | -$201.66M |
| Net income | -$65.78M | -$80.94M | -$29.73M | $9.35M | -$203.67M |
| EPS (diluted) | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $271.15M | $344.07M | $429.40M | $450.39M | $392.81M |
| Total liabilities | $57.16M | $103.09M | $150.89M | $180.07M | $164.60M |
| Shareholders’ equity | $213.99M | $240.98M | $278.51M | $270.31M | $228.21M |
| Cash and equivalents | $230.91M | $237.03M | $292.00M | $391.88M | $370.49M |
| Long-term debt | $20.78M | $25.00M | $25.91M | $30.22M | $45.13M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$74.27M | -$59.75M | -$18.10M | $31.99M | -$135.04M |
| Capital expenditure | -$230.0K | -$648.0K | -$2.90M | -$7.73M | -$3.41M |
| Free cash flow | -$74.50M | -$60.40M | -$21.00M | $24.27M | -$138.45M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARCT | $10.93 | -1.7% | 196.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcturus Therapeutics Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW